Patent Issued for Heterocyclic amides useful as protein modulators (USPTO 11970480).
In: Cancer Vaccine Week, 2024-05-20, S. 93-93
serialPeriodical
Zugriff:
A patent has been issued to GlaxoSmithKline Intellectual Property for heterocyclic amides that can modulate proteins involved in the immune response. The invention focuses on a compound that can activate or inhibit the production of type I interferons and other cytokines, which could be beneficial for the treatment of viral infections, autoimmune diseases, and cancer. The compound may also have potential applications in the treatment of allergic diseases and as a vaccine adjuvant. Additionally, the patent discusses the use of the compound in the topical treatment of skin cancers and viral infections, as well as its role in activating the immune response against tumors. [Extracted from the article]
Copyright of Cancer Vaccine Week is the property of NewsRx and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Titel: |
Patent Issued for Heterocyclic amides useful as protein modulators (USPTO 11970480).
|
---|---|
Zeitschrift: | Cancer Vaccine Week, 2024-05-20, S. 93-93 |
Veröffentlichung: | 2024 |
Medientyp: | serialPeriodical |
ISSN: | 1543-6810 (print) |
Schlagwort: |
|
Sonstiges: |
|